Hepatitis B Virus genotypic differences map structurally close to NRTI resistance hot spots.

Area of Science:

• Virology
• Molecular Biology
• Drug Discovery

Background:

• Chronic Hepatitis B Virus (HBV) infection affects 350 million globally, leading to liver cirrhosis and cancer.
• Current treatments, nucleoside reverse transcriptase inhibitors (NRTIs), suppress HBV replication but often result in drug resistance.
• NRTI resistance mutations in the HBV P gene can be linked to changes in the viral surface antigen (S gene) due to overlapping reading frames.

Purpose of the Study:

• To investigate the structural relationship between genotype-specific residues and nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations in Hepatitis B Virus (HBV).
• To understand how natural variations in HBV genotypes might influence the development of drug resistance.

Main Methods:

• A three-dimensional homology model of the catalytic core of HBV reverse transcriptase (RT) was constructed using HIV-1 RT as a template.
• Residues exhibiting variability across different HBV genotypes were mapped onto the HBV RT homology model.

Main Results:

• Genotypic variability residues were found to be located in close proximity to residues associated with NRTI resistance.
• This spatial proximity suggests a potential structural interplay between natural genotypic variations and the emergence of drug resistance.

Conclusions:

• The emergence of NRTI resistance mutations in HBV RT may be structurally constrained by interactions with genotype-specific residues.
• These findings highlight the complex interplay between HBV genotype and antiviral drug resistance, potentially informing future therapeutic strategies.